MRSN

Mersana Therapeutics (MRSN)

About Mersana Therapeutics (MRSN)

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Details

Daily high

$29.14

Daily low

$29.00

Price at open

$29.01

52 Week High

$40.25

52 Week Low

$5.21

Market cap

145.5M

Dividend yield

0.00%

Volume

14,008

Avg. volume

53,284

P/E ratio

-2.07

Mersana Therapeutics News